Recognizing and Managing Asymptomatic Left Ventricular Dysfunction

Albert, Nancy M.; Lewis, Connie
April 2008
Critical Care Nurse;Apr2008, Vol. 28 Issue 2, p20
Academic Journal
The article discusses the diagnosis and management of asymptomatic left ventricular systolic dysfunction (LVSD) after myocardial infarction. Asymptomatic LVSD pertains to a form of structural heart disease that is associated with the development of heart failure. The epidemiology and pathophysiology of LVSD are explored. The pharmacological and device therapies for asymptomatic LVSD after myorcardial infarction include angiotensin converting enzyme (ACE) inhibitors/angiotensin receptor blockers, β-adrenergic blockers and statins.


Related Articles

  • Silent Myocardial Ischemia: A Challenge in Management. Yalcinkaya, Emre; Celik, Murat; Bugan, Baris; Cecchi, Emanuele // Archives of Iranian Medicine (AIM);Nov2013, Vol. 16 Issue 11, p695 

    A letter to the editor is presented in response to the article "Cryptogenic Myocardial Infarction in Young Patients: Which is the Optimal Diagnostic and Therapeutic Management?," by C. Giglioli, S. Fatucchi, M. Stolcova, R. Mercuri, R. Abbate, and G. Galanti in the 2013 issue.

  • Takotsubo cardiomyopathy. Cuculi, F.; Lim, C. C. S.; Banning, A. P. // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;5/22/2010, Vol. 340 Issue 7756, p1095 

    The article offers clinical information on takotsubo cardiomyopathy, a condition characterized by acute, reversible left ventricular dysfunction that does not correlate with epicardial coronary artery blood supply. Takotsubo cardiomyopathy commonly affects postmenopausal women and is usually...

  • Diagnosing and Managing Acute Heart Failure Guidelines: NICE. SHAUGHNESSY, ALLEN F. // American Family Physician;2/15/2015, Vol. 91 Issue 4, p260 

    The article presents guidelines from the British National Institute for Health and Care Excellence (NICE) on how to diagnose and treat new onset acute heart failure. Topics discussed include the measurement of serum natriuretic peptide level followed by transthoracic echocardiography, treatment...

  • Diagnosis and Management of Diastolic Dysfunction and Heart Failure. Satpathy, Chhabi; Mishra, Trinath K.; Satpathy, Ruby; Satpathy, Hemant K.; Barone, Eugene // American Family Physician;3/1/2006, Vol. 73 Issue 5, p841 

    Diastolic heart failure occurs when signs and symptoms of heart failure are present but left ventricular systolic function is preserved (i.e., ejection fraction greater than 45 percent). The incidence of diastolic heart failure increases with age; therefore, 50 percent of older patients with...

  • Benefits and risks associated with β-blocker prophylaxis in noncardiac surgery. White, C. Michael; Talati, Ripple; Phung, Olivia J.; Baker, William L.; Reinhart, Kurt; Sedrakyan, Art; Kluger, Jeffrey; Coleman, Craig I. // American Journal of Health-System Pharmacy;4/1/2010, Vol. 67 Issue 7, p523 

    The article focuses on the benefits and risks factors associated with the use of B-blocker prophylaxis in noncardiac surgeries (NCSs). It discusses the clinical trials which evaluated the effect of perioperative B-blockers on myocardial infarction (MI), stroke, and hypotension. It says that...

  • A step-by-step guide to the heart failure care. Saunders, Carlos S.; Feldman, Arthur M. // Patient Care;6/15/2000, Vol. 34 Issue 11, p154 

    Presents a step by step guide for providing medical care during heart failure (HF). Use of two-dimensional echocardiography and Doppler flow imaging for diagnosis; Complex drug regimen needed for HF; Use of beta-blockers, spironolactone and higher dosages of angiotensin-converting enzyme. ...

  • Beta blockers, ACE inhibitors are still under-prescribed.  // Modern Medicine;Jan97, Vol. 65 Issue 1, p27 

    Reports on studies showing that beta blockers and angiotensin-converting enzyme (ACE) inhibitors are underutilized in treating heart diseases. Efficacy of beta blocker therapy in lowering post-myocardial infarction mortality in patients who do not undergo catheterization; Tendency of physicians...

  • Research finds puzzling racial differences in heart drug. Nano, Stephanie // Hudson Valley Business Journal;06/04/2001, Vol. 12 Issue 6, p25 

    Reports that North American research into racial differences in medicine found that a widely prescribed heart drug works poorly in blacks, while another such drug is just as effective in blacks as it is in nonblacks. Equal effectiveness shown by the beta blocker Coreg in reducing the risk of...

  • One-year cost of HF substantial in the US.  // PharmacoEconomics & Outcomes News;6/19/2005, Issue 455, p8 

    Presents a study which evaluated the cost of therapy for patients with heart failure in the U.S. Comparison of initial hospital costs for patients receiving doses of angiotensin converting enzyme inhibitors and beta-blockers than for those who received neither drug; Medical cost of therapy for...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics